Integrase strand transfer inhibitors in the management of HIV-positive individuals

Annals of Medicine

Volumn 46, Issue 3, 2014, Pages 123-129

  Mesplède, Thibault ^a   Quashie, Peter K ^a,b   Zanichelli, Veronica ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Dolutegravir; Drug resistance; Elvitegravir; HIV; Integrase strand transfer inhibitors; Raltegravir

Indexed keywords

ABACAVIR; ATAZANAVIR; COBICISTAT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TIPRANAVIR; FUSED HETEROCYCLIC RINGS;

ANTIVIRAL RESISTANCE; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS LOAD; HIV INFECTIONS;

DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 84899789677     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.883169     Document Type: Review

References (57)

1. Boyd SD. Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm. 2011; 68: 991-1001.
2. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011; 365: 637-46.
3. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008; 5: 114.
4. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287: 646-50.
5. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012; 10: 279-90.
6. Waters LJ, Barber TJ. Dolutegravir for treatment of HIV: SPRING forwards? Lancet. 2013; 381: 705-6.
7. Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012; 21: 395-401.
8. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012; 21: 523-30.
9. Wainberg MA, Quashie PK, Mesplede T. Dolutegravir HIV integrase inhibitor treatment of HIV infection. Drug Future. 2012; 37: 697-707.
10. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable effi cacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: fi nal 5-year results from STARTMRK. J Acquir Immune Defi c Syndr. 2013; 63: 77-85.
11. Messiaen P, Wensing A M, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis.PLoS One. 2013; 8: e52562.
12. Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, et al. In-vitro phenotypic suscept 1 ' non b ' integrase inhibitors naive clinicaLisolates to dolutegravir and raltegravir. AIDS. 2013 Aug
13. [Epub ahead of print]. Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, et al. Raltegravir andetravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009; 25: 225-7.
14. Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011; 11: 907-15.
15. Lennox J L, deJesus E, Lazzarin A, Pollard R B, Madruga J V, Berger D S, et al. Safety andeffi cacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374: 796-806.
16. Lennox J L, dejesus E, Berger D S, Lazzarin A, Pollard R B, Ramalho Madruga JV, et al. Raltegravir versus Efavirenz regimens in treatmentnaive HIV-1-infected patients: 96-week effi cacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defi c Syndr. 2010; 55: 39-48.
17. Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, et al. Effi cacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: fi nal results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013; 13: 587-96.
18. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral Effect of raltegravir aft er 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defi c Syndr. 2009; 52: 350-6.
19. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral Effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defi c Syndr. 2007; 46: 125-33.
20. Sax P E, deJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. C o-formulatedelvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulatedefavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results aft er 48 weeks. Lancet. 2012; 379: 2439-48.
21. Zolopa A, Sax PE, DeJesus E, Mills A, Cohen C, Wohl D, et al. A randomized double-blind comparison of coformulatedelvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defi c Syndr. 2013; 63: 96-100.
22. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulatedelvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulatedemtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379: 2429-38.
23. Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, et al. A randomized, double-blind comparison of coformulatedelvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulatedemtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defi c Syndr. 2013; 62: 483-6.
24. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012; 12: 111-18.
25. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013; 27: 1771-8.
26. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369: 1807-18.
27. Feinberg J, Clotet B, Khuong M, Antinori A, van Lunzen J, Dumitru I, et al. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral naive adults: 48 week results from FLAMINGO (ING114915). In 53rd ICAAC Conference ABSTRACT H-1464a; Denver, CO. 2013.
28. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013; 13: 927-35.
29. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013; 381: 735-43.
30. G uidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfonihgov/guidelines (accessed 10 December 2013).
31. Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard fi rst-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013; 381: 2091-9.
32. Paton N, Kityo C, Hoppe A, Hakim J, van Oosterhout J, Silka A, et al. A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial. In: 7th IAS Conference on HIV pathogenesis treatment and prevention, Abstract number: WELBB02, 30 June-03 July 2013; Kuala Lumpur, Malaysia. 2013.
33. Steigbigel R T, Cooper D A, Kumar P N, Eron J E, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359: 339-54.
34. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359: 355-65.
35. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term effi cacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010; 50: 605-12.
36. Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, et al. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure. Int J Antimicrob Agents. 2013; 42: 42-7.
37. Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2012; 12: 27-35.
38. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviralexperienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013; 382: 700-8.
39. Iwamoto M, Hanley WD, Petry AS, Friedman EJ, Kost JT, Breidinger SA, et al. Lack of a clinically important Effect of moderate hepatic insuffi-ciency and severe renaLinsuffi ciency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009; 53: 1747-52.
40. Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, et al. Minimal pharmacokinetic interaction between the human immunodefi ciency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008; 52: 4228-32.
41. Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, et al. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010; 54: 4619-25.
42. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012; 56: 3101-6.
43. Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, et al. Raltegravir pharmacokinetics in treatment-naive patients is not infl uenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Antimicrob Agents Chemother. 2013; 57: 784-8.
44. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS. 2012; 7: 390-400.
45. Min S, Sloan L, Dejesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011; 25: 1737-45.
46. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010; 54: 254-8.
47. Elion R, Molina JM, Ramon Arribas Lopez J, Cooper D, Maggiolo F, et al. A randomized phase 3 study comparing once-daily elvitegravir with twicedaily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defi c Syndr. 2013; 63: 4 94-7.
48. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinicaLimplications. J Infect Dis. 2011; 203: 1204-14.
49. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS. 2012; 7: 401-8.
50. Quashie PK, Mesplede T, Wainberg MA. HIV drug resistance and the advent of integrase inhibitors. Curr Infect Dis Rep. 2013; 15: 85-100.
51. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011; 55: 813-21.
52. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety andeffi cacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013; 207: 740-8.
53. Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fi tness. Antimicrob Agents Chemother. 2013; 57: 2654-63.
54. Nichols G, Mills A, Grossberg R, Lazzarin A, Maggiolo F, Molina J, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. In Eleventh International Congress on Drug Therapy in HIV Infection; Glasgow, SC. J Int AIDS Soc. 2013:18112.
55. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012; 86: 2696-705.
56. Mesplede T, Quashie P, Oliveira M, Wainberg M. HIV resistance to dolutegravir (DTG) simultaneously diminishes viral DNA integration into host cells and viral replication fi tness: implications for HIV reservoirs. In 7th IAS Conference on HIV pathogenesis treatment and Abstract number: MOPE014; 30 June-03 July 2013; Kuala Lumpur, Malaysia. 2013.
57. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, et al. Viral fi tness cost prevents HIV-1 from evading dolutegravir drug pressure . Retrovirology. 2013; 10: 22.